---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002780"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:23:39.400710+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Holdings FY2023 net loss $16.1M; cash drops to $1.1M from $10.4M

## Summary
- Net loss $16.1M ($33.63 per share) vs $13.9M ($38.12 per share) in FY2022.
- Cash at Dec 31, 2023: $1.1M, down from $10.4M a year earlier.
- R&D expense rose to $11.6M from $9.2M on manufacturing and trial enrollment.
- Completed first dose cohort in Phase 1/1b trial of BP1002 for AML and Phase 1 trial for lymphoma/CLL.
- G&A fell to $4.2M from $4.7M; net cash used in ops $11.5M.

## SEC filing metadata
- accession: 0001558370-24-002780
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/0001558370-24-002780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/bpth-20240308x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002780
- JSON: https://secwatch.observer/filing/0001558370-24-002780.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002780.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2023 results: net income $16.1 million, or $33.63 per share, EPS $33.63 per share.
  - Period: the year ended December 31, 2023
  - Net income: $16.1 million, or $33.63 per share
  - EPS: $33.63 per share
  - Result: reported results
  source text: The Company reported a net loss of $16.1 million, or $33.63 per share, for the year ended December 31, 2023, compared to a net loss of $13.9 million, or $38.12 per share, for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/0001558370-24-002780-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.